13F Holdings
中文EN

AZTR Azitra, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1701478 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-98.9%
TTM net income YoY20.5%
TTM EPS YoY71.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-146,468.5%
Net margin-119,566.6%
FCF margin-135,885.3%
EBITDA margin-144,793.5%

Returns

ROE-208.3%
ROA-143.8%
ROIC (approx.)-767.7%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets22.6%
Debt / equity0.00x
Current ratio3.80x
Interest coverage-903.38x

Cash quality & payout

Operating cash flow / net income1.14x
Accruals ratio19.5%
Payout ratio—
Capex / revenue114.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$0$7,500$686,000$284,000
R&D expense$4.84M$4.72M$3.64M$6.10M
SG&A expense$6.13M$6.27M$4.49M$3.64M
Operating income-$10.97M-$10.99M-$7.45M-$9.45M
Interest expense$7,587$12,160$167,726$251,891
Pretax income-$10.95M-$8.96M-$11.27M-$10.68M
Income tax$8,319$9,031$17,308—
Net income-$10.96M-$8.97M-$11.28M-$10.68M
EBITDA-$10.83M-$10.85M-$7.32M-$9.33M
EPS (basic)-2.25-15.70-54.98-12.74
EPS (diluted)-2.25-15.70-54.98-12.74
Weighted avg. shares (diluted)4.87M571,162229,8661.06M
Balance sheet
Cash & equivalents$2.07M$4.55M$1.80M$3.49M
Receivables$912$233—$175,000
Current assets$3.02M$5.23M$2.54M$4.14M
PP&E, net$548,591$653,957$710,075$846,958
Intangibles$316,673$246,420$210,881$219,567
Total assets$5.03M$7.36M$5.12M$7.17M
Current liabilities$1.07M$1.38M$1.60M$2.22M
Total liabilities$1.22M$1.66M$2.20M$9.73M
Shareholders' equity$3.80M$5.70M$2.91M-$36.26M
Shares outstanding1.07M1.15M403,2461.04M
Cash flow statement
Operating cash flow-$11.22M-$10.18M-$7.36M-$8.35M
Capital expenditure$24,213$8,569$26,544$33,101
Free cash flow-$11.25M-$10.19M-$7.39M-$8.38M
Investing cash flow-$182,909-$379,246-$318,259-$336,761
Financing cash flow$8.92M$13.32M$5.98M$4.13M
Depreciation & amortization$138,069$131,188$129,653$125,885
Stock-based compensation$62,744$245,053$151,505$184,465

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.